PRINCETON, NJ -- (MARKET WIRE) -- February 20, 2007 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced the issuance of United States Patent Number 7,179,475, entitled “Anhydrous Topical Skin Preparations.” This patent provides coverage for the specific formulation of ketoconazole in a waterless gel that Barrier Therapeutics markets in the U.S. under the trade name Xolegel™ (ketoconazole, USP) 2% Gel, for the treatment of seborrheic dermatitis.
